Academic Journal
Fusion gene heterogeneity and kinase enrichment in high-grade serous carcinomas.
| Τίτλος: | Fusion gene heterogeneity and kinase enrichment in high-grade serous carcinomas. |
|---|---|
| Συγγραφείς: | Panagopoulos I; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. Electronic address: ioapan@ous-hf.no., Stranger A; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. Electronic address: ane.stranger@ous-research.no., Sveen A; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: anita.sveen@medisin.uio.no., Jareid M; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. Electronic address: mielinn@gmail.com., Kidd SG; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. Electronic address: s.g.kidd@ous-research.no., Bischof K; Department of Surgical Oncology, Section of Gynaecological Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. Electronic address: katbis@ous-hf.no., Taskén K; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. Electronic address: kjetil.tasken@medisin.uio.no., Dørum A; Department of Surgical Oncology, Section of Gynaecological Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. Electronic address: dorumanne@gmail.com., Davidson B; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Pathology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. Electronic address: ben.davidson@medisin.uio.no., Lothe RA; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: r.a.lothe@medisin.uio.no., Skotheim RI; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway; Department of Informatics, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway. Electronic address: rolfis@uio.no., Johannessen B; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. Electronic address: bjarnej@uio.no. |
| Πηγή: | Neoplasia (New York, N.Y.) [Neoplasia] 2026 Sep; Vol. 79, pp. 101332. Date of Electronic Publication: 2026 Jun 25. |
| Τύπος έκδοσης: | Journal Article; Research Support, Non-U.S. Gov't |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Country of Publication: United States NLM ID: 100886622 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5586 (Electronic) Linking ISSN: 14765586 NLM ISO Abbreviation: Neoplasia Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2014- : [Amsterdam] : Elsevier Original Publication: New York, NY : Stockton Press, c1999- |
| Ιατρικοί όροι (MeSH): | Cystadenocarcinoma, Serous*/genetics , Cystadenocarcinoma, Serous*/pathology , Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/pathology , Oncogene Proteins, Fusion*/genetics , Protein Kinases*/genetics , Genetic Heterogeneity*, Biomarkers, Tumor/genetics ; Humans ; Female ; Neoplasm Grading |
| Περίληψη: | Genomic instability in high-grade serous tubo-ovarian carcinoma (HGSTOC) can generate fusion genes with potential roles in tumor evolution and clinical relevance. HGSTOCs commonly disseminate prior to diagnosis, but most studies analyze only one tumor sample per patient, limiting understanding of fusion gene dynamics. Here, RNA sequencing was performed on 108 tumor samples from multiple intra‑abdominal sites in 23 patients. A consensus approach involving three fusion callers identified 170 high-confidence fusion genes present in all samples from each patient, most of which were non‑recurrent and not in-frame. Protein kinases were significantly enriched among fusion partners, and commonly retained intact catalytic domains. Several of the kinase fusion genes may have oncogenic relevance, including AKAP8L::BRD4 (recurrent in three patients), GPBP1L1::MKNK1, SPAG16::ERBB4, UGP2::MAPK4, and STRN3::PRKD1. Four fusions involved homologous recombination-related genes, including FUT10::SPIDR, RAD54B::VIRMA, RAD54L::PLXNA2, and SMARCAD1::BOD1L1. Integration of these fusion genes with other somatic alterations in homologous recombination-related genes, deficiency signatures, and germline BRCA1/2 variants increased the involvement of the homologous recombination pathway to 15 HGSTOCs (65%). Overall, HGSTOC has a heterogeneous fusion gene landscape, and multi-site sampling with consensus calling offers a robust strategy for resolving fusion profiles. (Copyright © 2026 The Authors. Published by Elsevier Inc. All rights reserved.) |
| Competing Interests: | Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. |
| References: | Expert Opin Ther Pat. 2025 Apr;35(4):371-386. (PMID: 39918129) J Med Chem. 2025 Mar 13;68(5):5824-5844. (PMID: 40033556) Brief Bioinform. 2023 Jan 19;24(1):. (PMID: 36527429) Molecules. 2021 Dec 05;26(23):. (PMID: 34885957) Genome Res. 2002 Apr;12(4):656-64. (PMID: 11932250) Leukemia. 2023 Apr;37(4):905-909. (PMID: 36810896) Nucleic Acids Res. 2025 Jan 6;53(D1):D1243-D1249. (PMID: 39460617) Bioinformatics. 2007 Feb 15;23(4):401-7. (PMID: 17182697) Bioinformatics. 2015 Jan 15;31(2):166-9. (PMID: 25260700) Cell Rep. 2018 Apr 3;23(1):227-238.e3. (PMID: 29617662) Lancet Oncol. 2023 Sep;24(9):1018-1028. (PMID: 37657461) Science. 2002 Dec 6;298(5600):1912-34. (PMID: 12471243) Genome Biol. 2019 Oct 21;20(1):213. (PMID: 31639029) Mol Cell Pharmacol. 2015;7(2):15-20. (PMID: 27134695) NAR Cancer. 2024 May 31;6(2):zcae026. (PMID: 38828390) Mol Ther Nucleic Acids. 2020 Mar 6;19:1379-1398. (PMID: 32160708) J Cancer Res Clin Oncol. 2023 Sep;149(11):9509-9512. (PMID: 37162545) EMBO Rep. 2018 Oct;19(10):. (PMID: 30224410) Genes Dis. 2025 Jan 20;12(5):101536. (PMID: 40584293) Nucleic Acids Res. 2025 Jan 6;53(D1):D20-D29. (PMID: 39526373) Nature. 2011 Jun 29;474(7353):609-15. (PMID: 21720365) Genome Res. 2021 Mar;31(3):448-460. (PMID: 33441414) Nucleic Acids Res. 2025 Jan 6;53(D1):D672-D677. (PMID: 39417505) Nat Rev Drug Discov. 2023 May;22(5):357-386. (PMID: 36376561) Bioinformatics. 2014 Aug 1;30(15):2114-20. (PMID: 24695404) Genome Biol. 2014;15(12):550. (PMID: 25516281) J Pathol. 2010 May;221(1):49-56. (PMID: 20229506) Expert Opin Ther Targets. 2024 Mar;28(3):113-115. (PMID: 38421000) NAR Genom Bioinform. 2023 Oct 18;5(4):lqad093. (PMID: 37859801) Nat Methods. 2020 Mar;17(3):261-272. (PMID: 32015543) Nat Commun. 2023 Jul 20;14(1):4387. (PMID: 37474499) Bioinformatics. 2021 Oct 11;37(19):3353-3355. (PMID: 33772596) J Med Chem. 2023 Jan 12;66(1):122-139. (PMID: 36538005) Mol Cancer Res. 2019 Mar;17(3):676-685. (PMID: 30518629) Nucleic Acids Res. 2024 Jan 5;52(D1):D334-D344. (PMID: 37992291) Expert Opin Ther Pat. 2024 Oct;34(10):929-951. (PMID: 39219068) Nat Biotechnol. 2022 Aug;40(8):1276-1284. (PMID: 35379963) JCI Insight. 2024 Jan 4;9(3):. (PMID: 38175731) Nucleic Acids Res. 2025 Jan 6;53(D1):D966-D975. (PMID: 39565199) Int J Mol Sci. 2021 Apr 30;22(9):. (PMID: 33946483) Nat Commun. 2013;4:2612. (PMID: 24113773) Front Oncol. 2024 Dec 20;14:1514471. (PMID: 39759134) Mol Cancer. 2018 Oct 5;17(1):145. (PMID: 30290811) |
| Contributed Indexing: | Keywords: Fusion gene heterogeneity; High-grade serous tubo-ovarian carcinoma; Homologous recombination deficiency; Kinase enrichment; RNA sequencing |
| Substance Nomenclature: | 0 (Oncogene Proteins, Fusion) 0 (Biomarkers, Tumor) EC 2.7.- (Protein Kinases) |
| Entry Date(s): | Date Created: 20260625 Date Completed: 20260729 Latest Revision: 20260918 |
| Update Code: | 20260919 |
| PubMed Central ID: | PMC13325326 |
| DOI: | 10.1016/j.neo.2026.101332 |
| PMID: | 42349107 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!